Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis

Figures

• 

  Figure 1. Kaplan–Meier curves and log-rank test of PFS with respect to (a) metabolic PLC burden, (b) cPLC, and (c) clinical stage. PFS progression-free survival, PLC pulmonary lymphangitic carcinomatosis. *P < 0.05.

• 

  Figure 2. Comparison of Kaplan–Meier curves and log-rank test of PFS between (a) cPLC1 and cPLC2, (b) cPLC1 and cPLC3, and (c) cPLC2 and cPLC3. PFS progression-free survival, PLC pulmonary lymphangitic carcinomatosis. *P < 0.05.

• 

  Figure 3. Kaplan–Meier curves and log-rank test of OS with respect to age. OS overall survival. *P < 0.05.

• 

  Figure 4. Representative FDG PET/CT images (CT, PET, and fusion images) of cPLC, classified as (a) cPLC1, (b) cPLC2, and (c) cPLC3. (a) The primary tumor was in left upper lobe and PLC was located only in the same lobe where the primary tumor is located (white arrows). PLC SUVmax in the left upper lobe and metabolic PLC burden were 3.27 and 3.27, respectively. (b) The primary tumor was in right lower lobe and PLC was confined to right lower lobe and right middle lobe (gray arrows). PLC SUVmax in right lower lobe and metabolic PLC burden were 3.06 and 6.12, respectively. (c) The primary tumor was in left upper lobe and PLC was distributed throughout both lungs (black arrows). PLC SUVmax in left lower lobe and metabolic PLC burden were 3.77 and 18.85, respectively. FDG fluorine-18-fluorodeoxyglucose, PET positron emission tomography, CT computed tomography, PLC pulmonary lymphangitic carcinomatosis, SUVmax maximum standardized uptake value.